Transchem

Who are the top shareholders of the Transchem?

The top shareholders of Transchem are Priyanka Finance Private Limited with 40.11%, followed by Smit Capital Services Private Limited at 11.02%. Individual investors own 24.69%, with no pledged promoter holdings or shares held by mutual funds or foreign institutional investors.

The top shareholders of Transchem include Priyanka Finance Private Limited, which holds the largest stake at 40.11%. Following that, Smit Capital Services Private Limited is the highest public shareholder with an 11.02% ownership. Additionally, individual investors collectively hold 24.69% of the company's shares. Notably, there are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors holding shares.

Who are in the management team of Transchem?

As of March 2023, the management team of Transchem includes Bina Shah (Chairperson), Neerav Merchant (Independent Director), Neeraja Karandikar (Company Secretary & Compliance Officer), Mirza Saeed Kazi (Director), and Mahesh Suresh Rananavre (Whole-time Director). Each member contributes to the company's governance and operations.

As of March 2023, the management team of Transchem includes the following individuals:<BR><BR>1. Bina Shah - Chairperson<BR>2. Neerav Merchant - Independent Director<BR>3. Neeraja Karandikar - Company Secretary & Compliance Officer<BR>4. Mirza Saeed Kazi - Director<BR>5. Mahesh Suresh Rananavre - Whole-time Director<BR><BR>Each member plays a crucial role in the governance and operational oversight of the company.

What does Transchem do?

Transchem Ltd is a micro-cap company in the Pharmaceuticals & Biotechnology industry, focusing on mushroom production and processing, as well as chemicals and pharmaceuticals. As of March 2025, it reported net sales of 2 Cr and a net profit of 1 Cr, with a market cap of Rs 49 Cr.

Overview: <BR>Transchem Ltd is a micro-cap company operating in the Pharmaceuticals & Biotechnology industry, primarily engaged in the production and processing of mushrooms along with dealing in chemicals and pharmaceuticals.<BR><BR>History: <BR>Transchem Ltd was incorporated as a private limited company in 1976 and converted into a public limited company in 1992. The company diversified its activities in 1993 to focus on mushroom production and processing. The latest quarterly results reported net sales and net profit for March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 2 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 1 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: Rs 49 Cr (Micro Cap) <BR><BR>Key Metrics: <BR>P/E: 9.00 <BR>Industry P/E: 35 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.00 <BR>Return on Equity: 6.75% <BR>Price to Book: 0.63 <BR><BR>Contact Details: <BR>Address: 304 Ganatra Estate, Pokhran Road No.1 Khopat Thane (West) Maharashtra : 400601 <BR>Tel: 91-22-25477077 <BR>Email: secretaryu@transchem.net <BR>Website: http://www.transchem.net

Has Transchem declared dividend?

No Dividend History Available

Who are the peers of the Transchem?

Transchem's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Shelter Pharma, Chandra Bhagat, Vista Pharma, and Medicamen. Transchem has average management risk, below average growth, and a 1-year return of 7.69%, compared to its peers' varying performance.

Peers: The peers of Transchem are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Shelter Pharma, Chandra Bhagat, Vista Pharma., and Medicamen.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and Shelter Pharma, while Good management risk is found at Divi's Lab., Torrent Pharma, and Medicamen. Average management risk is noted for Transchem, and Below Average management risk is present at Chandra Bhagat and Vista Pharma. Growth is Excellent for Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and Medicamen, while Below Average growth is seen at Transchem, Torrent Pharma, Chandra Bhagat, and Vista Pharma. Finally, Excellent capital structure is noted for Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, and Shelter Pharma, while Below Average capital structure is found at Transchem, Chandra Bhagat, and Medicamen.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.69%, while Chandra Bhagat has the lowest at -42.15%. Transchem's 1-year return is 7.69%, which is significantly lower than Divi's Lab. and higher than Chandra Bhagat. Additionally, the six-month return is negative for Shelter Pharma, Chandra Bhagat, Vista Pharma., and Transchem.

Is Transchem overvalued or undervalued?

As of April 25, 2023, Transchem is considered a risky but undervalued investment with favorable valuation metrics, including a PE Ratio of 9.28, compared to its peers, despite recent underperformance against the Sensex.

As of 25 April 2023, the valuation grade for Transchem has moved from does not qualify to risky. The company is currently considered undervalued based on its financial metrics. Key ratios include a PE Ratio of 9.28, a Price to Book Value of 0.63, and a PEG Ratio of 0.39, indicating potential for growth relative to its price. <BR><BR>In comparison to its peers, Transchem's valuation appears favorable against Sun Pharma's PE Ratio of 35.25 and Divi's Lab's PE Ratio of 79.33, both of which are classified as expensive. Additionally, Transchem's EV to EBITDA ratio of -32.72 stands out as a notable outlier, suggesting significant challenges in profitability relative to its enterprise value. Despite recent underperformance against the Sensex, with a year-to-date return of -22.30% compared to the Sensex's 5.59%, the overall valuation metrics suggest that Transchem may present an attractive opportunity for investors.

What is the technical trend for Transchem?

As of June 2, 2025, Transchem's technical trend has shifted to mildly bearish, influenced by daily moving averages and weekly Bollinger Bands indicating bearish conditions, despite some mildly bullish signals from the weekly MACD and KST.

As of 2 June 2025, the technical trend for Transchem has changed from sideways to mildly bearish. The current stance is mildly bearish, driven primarily by the daily moving averages indicating a bearish trend and the weekly Bollinger Bands also signaling bearish conditions. While the weekly MACD and KST are mildly bullish, they are offset by the overall bearish indicators. The stock has experienced a significant decline year-to-date, further supporting the bearish outlook.

How big is Transchem?

As of 24th July, Transchem Ltd has a market capitalization of 54.00 Cr, with Net Sales of 2.63 Cr and a Net Profit of 5.22 Cr reported in the latest four quarters. Shareholder's Funds are 75.65 Cr and Total Assets are 76.32 Cr as of March 2024.

As of 24th July, Transchem Ltd has a market capitalization of 54.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Transchem reported Net Sales of 2.63 Cr and a Net Profit of 5.22 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, with Shareholder's Funds amounting to 75.65 Cr and Total Assets at 76.32 Cr.

How has been the historical performance of Transchem?

Transchem's historical performance shows significant growth, with net sales and total operating income reaching 2.63 Cr in March 2025, up from 0.41 Cr in March 2024. Despite increased expenditures, the company reported improved profits, with profit after tax rising to 5.23 Cr and a net cash inflow of 42 Cr, indicating a positive trend in revenue and profitability.

Answer:<BR>The historical performance of Transchem shows a significant increase in net sales, reaching 2.63 Cr in March 2025, up from 0.41 Cr in March 2024, and starting from zero in previous years. Total operating income also rose to 2.63 Cr in March 2025, reflecting the same trend. However, total expenditure increased to 4.09 Cr in March 2025, leading to an operating profit (PBDIT) of 7.07 Cr, which is an improvement from 5.67 Cr in March 2024. The profit before tax for March 2025 was 7.06 Cr, up from 5.65 Cr in the prior year, while profit after tax reached 5.23 Cr, compared to 4.20 Cr in March 2024. The earnings per share (EPS) increased to 4.27 in March 2025 from 3.43 in March 2024. <BR><BR>In terms of assets and liabilities, total assets grew to 79.73 Cr in March 2025, up from 76.32 Cr in March 2024, with total liabilities also increasing to 79.73 Cr. The company maintained a stable equity capital of 12.24 Cr across the years. Cash flow from operating activities improved significantly to 36 Cr in March 2025, compared to a negative 39 Cr in March 2024, contributing to a net cash inflow of 42 Cr in March 2025, a notable recovery from a net outflow of 34 Cr in the previous year. Overall, Transchem's financial performance indicates a positive trend in revenue generation and profitability, despite rising expenditures.<BR><BR>Breakdown:<BR>Transchem's financial performance has shown a remarkable upward trajectory in net sales, which surged to 2.63 Cr in March 2025 from 0.41 Cr in March 2024, marking a significant recovery from previous years where sales were non-existent. Total operating income mirrored this growth, reaching 2.63 Cr in March 2025. Despite the increase in total expenditure to 4.09 Cr, the company reported an operating profit (PBDIT) of 7.07 Cr, up from 5.67 Cr in the prior year, indicating improved operational efficiency. Profit before tax also rose to 7.06 Cr, while profit after tax reached 5.23 Cr, reflecting a healthy increase from 4.20 Cr in March 2024. The earnings per share (EPS) rose to 4.27, further showcasing the company's profitability. On the balance sheet, total assets increased to 79.73 Cr, with total liabilities matching this figure, indicating a stable financial position. Cash flow from operating activities saw a significant turnaround, resulting in a net cash inflow of 42 Cr in March 2025, a stark contrast to the previous year's outflow. Overall, Transchem's financial metrics indicate a positive trend in both revenue and profitability, despite rising costs.

When is the next results date for Transchem Ltd?

The next results date for Transchem Ltd is 07 February 2026.

The next results date for Transchem Ltd is scheduled for 07 February 2026.

Are Transchem Ltd latest results good or bad?

Transchem Ltd's latest results are concerning, with a net profit decline of 31.31% and zero net sales for two consecutive quarters, indicating a lack of operational revenue and raising serious doubts about its future viability. Overall, the financial performance is poor, reflecting significant instability.

Transchem Ltd's latest results indicate a concerning financial situation. In Q2 FY26, the company reported a net profit of ₹0.68 crore, which represents a significant decline of 31.31% quarter-on-quarter. More critically, net sales stood at zero, continuing a trend of no operational revenue for two consecutive quarters. This stark absence of sales is a major red flag, especially when compared to the previous quarter where they had reported some sales.<BR><BR>The company's reliance on other income, which amounted to ₹1.68 crore in the latest quarter, highlights its precarious position as it depends entirely on non-operational sources for profitability. The return on equity (ROE) is also weak at 4.68%, indicating poor capital efficiency.<BR><BR>Overall, the financial performance suggests that Transchem is functioning more as a cash shell rather than an active business entity, raising serious concerns about its future viability and operational strategy. Given these factors, the latest results can be characterized as bad, reflecting a lack of sustainable business operations and growing financial instability.

Should I buy, sell or hold Transchem Ltd?

Why is Transchem Ltd falling/rising?

As of 04-Mar, Transchem Ltd's stock price is currently at 177.40, reflecting a decline of 1.99%. The stock has underperformed recently, losing 3.93% over the last two days and 1.74% over the past month, despite a strong long-term performance.

As of 04-Mar, Transchem Ltd's stock price is falling, currently at 177.40, which reflects a decrease of 3.6 points or 1.99%. The stock has been underperforming, having lost 3.93% over the last two days and has consistently fallen for the past two days. Additionally, the stock's performance today has underperformed its sector by 0.9%. <BR><BR>In terms of broader market performance, Transchem Ltd has shown a decline of 1.74% over the past month and 3.12% year-to-date, while the benchmark Sensex has also experienced losses, albeit at a higher rate. Despite its strong performance over the longer term, with a remarkable increase of 349.57% over the past year and 639.78% over three years, the recent trends indicate a downturn. <BR><BR>The stock's trading activity shows that it opened at 177.40 and has remained at this price without any range fluctuations. Although there has been a slight increase in delivery volume, indicating rising investor participation, it has not been sufficient to counteract the recent price declines. Overall, the combination of consecutive falls, underperformance relative to the sector, and recent trading patterns contribute to the current downward movement in Transchem Ltd's stock price.

Which are the latest news on Transchem?